PureTech Health plc (NASDAQ:PRTC - Get Free Report)'s share price gapped up before the market opened on Monday . The stock had previously closed at $20.35, but opened at $22.73. PureTech Health shares last traded at $23.12, with a volume of 11,986 shares trading hands.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on the stock. Leerink Partnrs raised shares of PureTech Health to a "strong-buy" rating in a research note on Monday, September 9th. Leerink Partners assumed coverage on shares of PureTech Health in a research note on Monday, September 9th. They set an "outperform" rating and a $45.00 price objective on the stock.
Get Our Latest Analysis on PRTC
PureTech Health Price Performance
The company has a 50-day moving average price of $21.21 and a 200 day moving average price of $22.49.
Hedge Funds Weigh In On PureTech Health
An institutional investor recently bought a new position in PureTech Health stock. Birch Hill Investment Advisors LLC bought a new stake in shares of PureTech Health plc (NASDAQ:PRTC - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 302,000 shares of the company's stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned approximately 1.26% of PureTech Health at the end of the most recent reporting period. 0.04% of the stock is owned by institutional investors and hedge funds.
About PureTech Health
(
Get Free Report)
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
See Also
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
